← Back to Search

CAR T-cell Therapy

IMA202 Product for Cancer (ACTengine Trial)

Phase 1

Waitlist Available

Research Sponsored by Immatics US, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years post treatment

Awards & highlights

ACTengine Trial Summary

This trial will test the safety of a new drug, IMA202, in patients with solid tumors that express a protein called MAGEA1.

Eligible Conditions

Cancer
Solid Tumors

ACTengine Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years post treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years post treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events (AE)

Secondary outcome measures

Persistence of T-cells

Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST)

ACTengine Trial Design

1Treatment groups

Experimental Treatment

Group I: Experimental: IMA202 ProductExperimental Treatment2 Interventions

Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated. Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

IMADetect®

2019

Completed Phase 1

~30

IMA202 Product

2019

Completed Phase 1

~20

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Immatics US, Inc.Lead Sponsor

4 Previous Clinical Trials

473 Total Patients Enrolled

Cedrik Britten, MDStudy DirectorImmatics US, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any known hazards related to using IMA202 Product therapeutically?

"Considering the fact that IMA202 Product is only in Phase 1 of its trials, Power has rated the drug's safety as low with a score of 1. This means there is limited evidence to support its efficacy and safety."

Answered by AI

Are researchers currently in the process of recruiting for this clinical trial?

"Hosted on clinicaltrials.gov, the details of this medical trial show that it is no longer recruiting participants; its initial posting was May 2nd 2019 and last edited July 20th 2022. However, there are currently 1,644 other studies actively in search of volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

TCR-engineered T Cells in Solid Tumors: IMA202-101

2019. "TCR-engineered T Cells in Solid Tumors: IMA202-101". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03441100.